Series-A Investment for Munich-based Medical Technology Startup Mecuris
January 16, 2019
Mecuris GmbH, a commercial-stage Munich-based medical technology startup focusing on the digitalization of prosthetics and orthotics, successfully completes its Series-A financing round of EUR 3.6m. In addition to existing seed investors Bayern Kapital and High-Tech Gründerfonds (HTGF), the new investors Vesalius Biocapital, Mulcan International Investments and one of the Top 5 hospital chains in Germany support now the innovative Mecuris approach.
Every patient is unique! Therefore, the demands placed on orthopedic technicians (OT) to care for patient’s needs are equally diverse. Cost and time pressure make it difficult to deal with these complex and patient-specific tasks. Less than perfectly fitting off-the-shelf orthotic or prosthetic products are hence delivered to the patients.
This is where Mecuris, a medical technology start-up, is improving the patients´ care substantially while saving significant time and money in the process. The company specializes in providing orthopedic technicians with an easy-to-use online platform for customizable and 3D-printed orthotics and prosthetics – delivered by Mecuris within days. Moreover, it provides solutions within a digital process chain resulting in a faster time to market for new products. Mecuris’ aim is to co-create patient-specific orthoses and prostheses with orthopedic technicians. As these can be further styled individually (color, texture, ornaments, logos, etc.) they will enrich the wearers’ life as an expression of their personality.
The approach to use and monetize digitalization for providing personalized orthotics and prosthetics to orthopedic technicians and patients has convinced the new and existing investors. In the Series A financing the Mecuris founding partners were able to attract three new investors: Vesalius Biocapital III SICAR, MII Mulcan International Investments GmbH, and one of the largest hospital chains in Germany and Europe. The latter aims to enable digitalization for its partners – the medical supply stores. In addition, the Seed-investors Bayern Kapital GmbH and High-Tech Gründerfonds Management GmbH (HTGF) have continued to commit themselves to the company’s goals.
Mecuris will use the proceeds of the financing round to penetrate the European market and increase sales. Furthermore, the start-up will continue to develop digital solutions to complement its portfolio and close gaps in the market that other players haven’t addressed yet.
About Mecuris GmbH
Mecuris teams up with certified prosthetists and orthotists (CPOs) to move orthopaedic care into the digital age. Bringing together 3D technologies into one intuitive Mecuris Solution Platform the company found a way to simplify the CPOs work and transform the way to design and use orthopaedic devices. Mecuris enriches wearers’ lives by enabling medical professionals to design their product ideas on our intuitive digital platform – without any CAD design knowledge. This means patients can quickly regain their mobility, show their individuality and become active again faster. Thanks to full CE-mark and ISO certification, Mecuris’ products meet the highest safety standards and are reimbursed by all health insurance funds in Germany.
Mecuris – You. Create.
Head of Marketing
T: +49 89 552623-86
About Bayern Kapital GmbH
Bayern Kapital GmbH, based in Landshut, was founded on the initiative of the Bavarian government in 1995. It is a wholly-owned subsidiary of the Bavarian LfA Förderbank . As the venture capital organisation of the Land of Bavaria, Bayern Kapital provides equity capital financing for the founders of young innovative technology companies in Bavaria.
Presently Bayern Kapital manages eleven investment funds with a total volume of around €325m. So far, it has invested almost €290m in 265 innovative companies in the fields of technology in various sectors including life science, software and IT, medical technology, materials and new materials, nanotechnology and environmental technology.
In this way, more than 5000 long-term jobs in sustainable companies have been created in Bavaria.
About MII Mulcan International Investments GmbH
MULCAN is an international investment company focusing on growth investment opportunities in the manufacturing, industrial and service sectors across Europe (with specific emphasis on Eastern Europe), the Middle East and in other developing countries.
About Vesalius Biocapital Partners S.à r.L,
Vesalius Biocapital (Vesalius), the specialist life sciences venture capital investor, has supported companies active in human health through venture capital funds since 2007. Since inception, Vesalius has raised over €260 million in three funds and contributed to the development of over 25 companies. The investment portfolio is well balanced between drug development and non-drug development investments and committed to providing capital to science-backed innovation and ambitious entrepreneurs, with a strong focus on an exit within five years.
About High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With EUR 892.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge 500 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and start-up experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in a range of sectors, including software, hardware and life sciences / chemistry.
This group also includes a number of success stories, such as Mister Spex, Rigontec, 6Wunderkinder, Next Kraftwerke and Cumulocity, as well as Juniqe, an online shop for art enthusiasts. To date, external investors have injected over EUR 1.9 billion into the HTGF portfolio via about 1,400 follow-on financing rounds.
Stay up to date
Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!